Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
CI-1040
60
CHF
CHF 60.00
In stock
SYN-1031-M0011 mgCHF 60.00
SYN-1031-M0055 mgCHF 84.00
SYN-1031-M01010 mgCHF 144.00
SYN-1031-M05050 mgCHF 515.00
SYN-1031-M100100 mgCHF 760.00

Product Details | |
---|---|
Synonyms | PD-184352; CI-1040 |
Product Type | Chemical |
Properties | |
Formula | C17H14ClF2IN2O2 |
MW | 478.7 |
CAS | 212631-79-3 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: MEK - MKK4&7 - MKK3&6 - MEK5 - MEK2 - MEK1 | Kinase Group: STE | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | GFMMXOIFOQCCGU-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of MEK1/2, which is a key component of the ERK/MAPK pathway. It has an IC(50) of 17nM.
Product References
- Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia: M. Milella, et al.; Blood 99, 3461 (2002)